Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5092453 | 0.95 | CD274 (0.53) | CD274KMT2AMEN1HTTRAB9A | |
| SCHEMBL5098454 | 0.92 | CD274 (0.63) | CD274KMT2AMEN1HTTRAB9A | |
| SCHEMBL5096309 | 0.89 | CD274 (0.75) | CD274KMT2AMEN1HTTRAB9A | |
| SCHEMBL5099020 | 0.89 | KMT2A (0.62) | CD274KMT2AMEN1HTTRAB9A | |
| SCHEMBL5092365 | 0.86 | CD274 (0.56) | CD274KMT2AMEN1HTTRAB9A | |
| SCHEMBL5096351 | 0.84 | CD274 (0.67) | CD274KMT2AMEN1HTTRAB9A | |
| SCHEMBL5105124 | 0.83 | KMT2A (0.59) | CD274KMT2AMEN1HTTRAB9A | |
| SCHEMBL5092534 | 0.82 | CD274 (0.55) | CD274KMT2AMEN1HTTRAB9A | |
| SCHEMBL5096391 | 0.82 | CD274 (0.60) | CD274KMT2AMEN1RAB9A | |
| SCHEMBL5105213 | 0.79 | ALDH1A1 (0.58) | CD274KMT2AMEN1HTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7411091-B2 | N-acyl-N′-benzyl-alkylendiamino derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2008-08-12 | — | — | US | claimed |
| EP-1689708-B1 | N-ACYL-N -BENZYL-ALKYLENDIAMINO DERIVATIVES | NEWRON PHARM SPA (IT) | 2007-06-27 | — | — | EP | claimed |
| US-20070142455-A1 | N-acyl-n'-benzyl-alkylendiamino derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-21 | — | — | US | claimed |
| EP-1689708-A1 | N-ACYL-N -BENZYL-ALKYLENDIAMINO DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-16 | — | — | EP | claimed |
| WO-2005054189-A1 | N-ACYL-N'-BENZYL-ALKYLENDIAMINO DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-16 | — | — | WO | claimed |
| EP-1535908-A1 | N-acyl-N'-benzyl-alkylendiamino drivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-06-01 | — | — | EP | claimed |
| US-7411091-B2 | N-acyl-N′-benzyl-alkylendiamino derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2008-08-12 | — | — | US | disclosed |
| EP-1689708-B1 | N-ACYL-N -BENZYL-ALKYLENDIAMINO DERIVATIVES | NEWRON PHARM SPA (IT) | 2007-06-27 | — | — | EP | disclosed |
| US-20070142455-A1 | N-acyl-n'-benzyl-alkylendiamino derivatives | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2007-06-21 | — | — | US | disclosed |
| EP-1689708-A1 | N-ACYL-N -BENZYL-ALKYLENDIAMINO DERIVATIVES | Newron Pharmaceuticals S.p.A. (IT) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005054189-A1 | N-ACYL-N'-BENZYL-ALKYLENDIAMINO DERIVATIVES | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2005-06-16 | — | — | WO | disclosed |
| EP-1535908-A1 | N-acyl-N'-benzyl-alkylendiamino drivatives | Newron Pharmaceuticals S.p.A. (IT) | 2005-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142455-A1 | N-acyl-n'-benzyl-alkylendiamino derivatives | SCN7A, HTR7, TRPC7 | CD274 4861/4885KMT2A 4198/4885MEN1 718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.